FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 338:908-909 March 26, 1998 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Schwartz, S. Related Article by Inzucchi, S. E. PubMed Citation

Type II (non-insulin-dependent) diabetes mellitus is characterized by insulin resistance, increased hepatic glucose production, and impaired secretion of insulin by pancreatic beta cells. Although the primary defect underlying these abnormalities is still not known, previous longitudinal studies have indicated that insulin resistance precedes any evidence of glucose intolerance in most patients.

The goal of oral therapy with antidiabetic drugs is to lower blood glucose concentrations toward normal by improving the pathophysiologic abnormalities. Several classes of drugs are now available for the management of type II diabetes mellitus. The oldest are the sulfonylurea compounds. Although they may have some extrapancreatic actions, . . . [Full Text of this Article]

References

Related Letters:

Pleuropulmonary Disease in a Man with Diabetes Who Was Treated with Troglitazone
Koshida H., Shibata K., Kametani T., Whitcomb R. W.
Extract | Full Text  
N Engl J Med 1998; 339:1400, Nov 5, 1998. Correspondence

This article has been cited by other articles:

• Kim, J. K., Fillmore, J. J., Gavrilova, O., Chao, L., Higashimori, T., Choi, H., Kim, H.-J., Yu, C., Chen, Y., Qu, X., Haluzik, M., Reitman, M. L., Shulman, G. I. (2003). Differential Effects of Rosiglitazone on Skeletal Muscle and Liver Insulin Resistance in A-ZIP/F-1 Fatless Mice. Diabetes 52: 1311-1318 [Abstract] [Full Text]  
• Jagannath, S., Rai, R. (2000). Rapid-Onset Subfulminant Liver Failure Associated with Troglitazone. ANN INTERN MED 132: 677-677 [Full Text]  
• Stewart, A. (1999). Creating your own medical Internet library. CMAJ 161: 1155-1160 [Abstract] [Full Text]  
• Psaty, B. M., Weiss, N. S., Furberg, C. D., Koepsell, T. D., Siscovick, D. S., Rosendaal, F. R., Smith, N. L., Heckbert, S. R., Kaplan, R. C., Lin, D., Fleming, T. R., Wagner, E. H. (1999). Surrogate End Points, Health Outcomes, and the Drug-Approval Process for the Treatment of Risk Factors for Cardiovascular Disease. JAMA 282: 786-790 [Full Text]  
• Mahler, R. J., Adler, M. L. (1999). Type 2 Diabetes Mellitus: Update on Diagnosis, Pathophysiology, and Treatment. J. Clin. Endocrinol. Metab. 84: 1165-1171 [Full Text]  
• Neuschwander-Tetri, B. A., Isley, W. L., Oki, J. C. (1999). Troglitazone-Associated Hepatic Failure. ANN INTERN MED 130: 330-330 [Full Text]  
• Luo, J., Cheung, J., Yevich, E. M., Clark, J. P., Tsai, J., Lapresca, P., Ubillas, R. P., Fort, D. M., Carlson, T. J,, Hector, R. F., King, S. R., Mendez, C. D., Jolad, S. D., Reaven, G. M. (1999). Novel Terpenoid-Type Quinones Isolated from Pycnanthus angolensis of Potential Utility in the Treatment of Type 2 Diabetes. J. Pharmacol. Exp. Ther. 288: 529-534 [Abstract] [Full Text]  
• Koshida, H., Shibata, K., Kametani, T., Whitcomb, R. W. (1998). Pleuropulmonary Disease in a Man with Diabetes Who Was Treated with Troglitazone. NEJM 339: 1400-1400 [Full Text]